NASDAQ:KALA KALA BIO (KALA) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free KALA Stock Alerts $7.85 -0.03 (-0.38%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$7.70▼$8.0050-Day Range$6.87▼$8.3952-Week Range$5.10▼$19.57Volume8,552 shsAverage Volume17,602 shsMarket Capitalization$21.12 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get KALA BIO alerts: Email Address KALA BIO MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside180.3% Upside$22.00 Price TargetShort InterestHealthy0.52% of Float Sold ShortDividend StrengthN/ASustainability-1.35Upright™ Environmental ScoreNews Sentiment-0.14Based on 3 Articles This WeekInsider TradingSelling Shares$38,817 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($18.03) to ($11.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.42 out of 5 starsMedical Sector119th out of 939 stocksPharmaceutical Preparations Industry46th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingKALA BIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.00, KALA BIO has a forecasted upside of 180.3% from its current price of $7.85.Amount of Analyst CoverageKALA BIO has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.52% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in KALA BIO has recently increased by 22.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKALA BIO does not currently pay a dividend.Dividend GrowthKALA BIO does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKALA BIO has received a 66.18% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Glucocorticoids" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for KALA BIO is -1.35. Previous Next 2.1 News and Social Media Coverage News SentimentKALA BIO has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for KALA BIO this week, compared to 1 article on an average week.Search Interest8 people have searched for KALA on MarketBeat in the last 30 days. MarketBeat Follows2 people have added KALA BIO to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, KALA BIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,817.00 in company stock.Percentage Held by Insiders13.40% of the stock of KALA BIO is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 24.61% of the stock of KALA BIO is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for KALA BIO are expected to grow in the coming year, from ($18.03) to ($11.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KALA BIO is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KALA BIO is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKALA BIO has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About KALA BIO Stock (NASDAQ:KALA)KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Read More KALA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KALA Stock News HeadlinesMarch 21, 2024 | msn.com"All I See Are A Number Of Inaccurate Statements": 11 Celebrities Who Were Accused Of Lying About Their Background And UpbringingMarch 18, 2024 | msn.comGame of Thrones' Nathalie Emmanuel unveils short hair transformationMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 14, 2024 | msn.com2024 NAACP Image Awards: The Complete Winners ListMarch 12, 2024 | msn.comDenise Austin, 67, Demonstrates ‘Low-Impact’ Burpee in Latest Workout VideoFebruary 26, 2024 | globenewswire.comKALA BIO to Present at TD Cowen 44th Annual Healthcare ConferenceFebruary 23, 2024 | benzinga.comKala Bio Stock (NASDAQ:KALA), Short Interest ReportFebruary 22, 2024 | msn.comFirst trailer for Outlander star Lauren Lyle's shark thrillerMarch 28, 2024 | Behind the Markets (Ad)The Small Biotech with a BIG Cancer SolutionThere's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.February 20, 2024 | msn.comHere Are the Top 6 ‘Bachelor’ Contestants Still in the Running for Joey’s HeartFebruary 13, 2024 | msn.comPatrick and Brittany Mahomes’ History With Travis Kelce’s Ex Kayla Nicole ExplainedFebruary 11, 2024 | msn.comTravis Kelce's Ex Kayla Nicole Parties with Wives of San Francisco 49ers Players Ahead of 2024 Super BowlFebruary 8, 2024 | msn.comSundance 2024 Slate Includes Films Starring Normani, André Holland, Mary J. Blige, Aunjanue Ellis-Taylor And MoreFebruary 6, 2024 | finance.yahoo.comKALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 5, 2024 | msn.comVictoria Monét Brings Her 2½-Year-Old Daughter Hazel to 2024 Grammys After She Became Youngest NomineeFebruary 2, 2024 | msn.com15 Best Heels for Wide Feet That Are Comfy and Stylish, According to PodiatristsJanuary 31, 2024 | msn.comSpringfield Veteran Services Director Tom Belton announces retirementJanuary 31, 2024 | msn.comHit a pothole? Report it to your local DPWJanuary 31, 2024 | msn.comForget crunches — this 10-minute bodyweight ab workout sculpts a strong core without putting pressure on your backJanuary 25, 2024 | msn.comSee All The 'Bachelor' Contestants Joey Smooched On Night OneJanuary 15, 2024 | au.news.yahoo.comJason Segel and Girlfriend Kayla Radomski Pose in Glam Looks While Holding Hands on Emmys Red CarpetJanuary 5, 2024 | msn.com‘Speed Racer’ Actor Christian Oliver Dies in Plane Crash With 2 Young DaughtersDecember 27, 2023 | msn.comColoradans teaching unity through celebrating KwanzaaDecember 27, 2023 | benzinga.comKala Bio Stock (NASDAQ:KALA), Guidance and ForecastDecember 21, 2023 | msn.comCincinnati area guidance counselor to appear on 'The Bachelor' this season. How to watchDecember 20, 2023 | yahoo.comThe Bachelor Season 28: Meet the 32 Women Fighting for Joey Graziadei’s HeartDecember 9, 2023 | morningstar.comKala Bio IncSee More Headlines Receive KALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KALA BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/27/2024Next Earnings (Estimated)3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KALA CUSIPN/A CIK1479419 Webwww.kalarx.com Phone(781) 996-5252Fax781-642-0399Employees34Year FoundedN/APrice Target and Rating Average Stock Price Target$22.00 High Stock Price Target$22.00 Low Stock Price Target$22.00 Potential Upside/Downside+180.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($22.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,820,000.00 Net MarginsN/A Pretax Margin-2,056.67% Return on Equity-259.42% Return on Assets-64.39% Debt Debt-to-Equity Ratio3.36 Current Ratio5.62 Quick Ratio5.62 Sales & Book Value Annual Sales$3.89 million Price / Sales5.43 Cash FlowN/A Price / Cash FlowN/A Book Value$11.12 per share Price / Book0.71Miscellaneous Outstanding Shares2,690,000Free Float2,332,000Market Cap$21.12 million OptionableNot Optionable Beta-1.86 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Mark T. Iwicki (Age 58)Chairman & CEO Comp: $1.1MMr. Todd Bazemore (Age 54)President & COO Comp: $783.04kDr. Kim Brazzell Ph.D. (Age 71)Head of R&D and Chief Medical Officer Comp: $750.91kDr. Justin Hanes Ph.D.Founder & Chair of the Scientific Advisory BoardMs. Mary Reumuth CPA (Age 49)CFO & Treasurer Ms. Jill S. SteierExecutive Director of Investor Relations & Corporate CommunicationsMr. Eric L. Trachtenberg (Age 51)Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Comp: $646.56kMr. Vincent Kosewski (Age 61)Senior VP of Manufacturing & Supply Chain Management Mr. Darius Kharabi J.D. (Age 44)M.B.A., Chief Business Officer Dr. Francis S. Mah M.D.Chief Medical AdvisorMore ExecutivesKey CompetitorsBullfrog AINASDAQ:BFRGBioVieNASDAQ:BIVIOncternal TherapeuticsNASDAQ:ONCTIterum TherapeuticsNASDAQ:ITRMNeuroBo PharmaceuticalsNASDAQ:NRBOView All CompetitorsInsiders & InstitutionsTower Research Capital LLC TRC Bought 4,357 shares on 2/13/2024Ownership: 0.162%Knights of Columbus Asset Advisors LLCBought 2,417 shares on 1/31/2024Ownership: 0.180%Mark T IwickiSold 4,539 sharesTotal: $30,547.47 ($6.73/share)Eric TrachtenbergSold 1,227 sharesTotal: $8,269.98 ($6.74/share)View All Insider TransactionsView All Institutional Transactions KALA Stock Analysis - Frequently Asked Questions Should I buy or sell KALA BIO stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KALA BIO in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KALA shares. View KALA analyst ratings or view top-rated stocks. What is KALA BIO's stock price target for 2024? 1 Wall Street analysts have issued 12-month price objectives for KALA BIO's shares. Their KALA share price targets range from $22.00 to $22.00. On average, they anticipate the company's share price to reach $22.00 in the next year. This suggests a possible upside of 180.3% from the stock's current price. View analysts price targets for KALA or view top-rated stocks among Wall Street analysts. How have KALA shares performed in 2024? KALA BIO's stock was trading at $7.00 at the beginning of the year. Since then, KALA shares have increased by 12.1% and is now trading at $7.85. View the best growth stocks for 2024 here. Are investors shorting KALA BIO? KALA BIO saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 12,100 shares, an increase of 22.2% from the February 29th total of 9,900 shares. Based on an average trading volume of 31,300 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.5% of the company's shares are short sold. View KALA BIO's Short Interest. When is KALA BIO's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our KALA earnings forecast. How were KALA BIO's earnings last quarter? KALA BIO, Inc. (NASDAQ:KALA) issued its quarterly earnings data on Monday, November, 15th. The company reported ($10.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($11.25) by $0.50. The company earned $3.07 million during the quarter, compared to analyst estimates of $5.18 million. During the same period last year, the business posted ($12.50) EPS. When did KALA BIO's stock split? KALA BIO's stock reverse split on Friday, October 21st 2022. The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What is Mark Iwicki's approval rating as KALA BIO's CEO? 1 employees have rated KALA BIO Chief Executive Officer Mark Iwicki on Glassdoor.com. Mark Iwicki has an approval rating of 100% among the company's employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of KALA BIO own? Based on aggregate information from My MarketBeat watchlists, some companies that other KALA BIO investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV). When did KALA BIO IPO? KALA BIO (KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. Who are KALA BIO's major shareholders? KALA BIO's stock is owned by many different retail and institutional investors. Top institutional investors include Knights of Columbus Asset Advisors LLC (0.18%), Tower Research Capital LLC TRC (0.16%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eric Trachtenberg, Hongming Chen, Mark T Iwicki, Mark T Iwicki, Mary Reumuth, Ra Capital Management, LP, Romulus K Brazzell and Todd Bazemore. View institutional ownership trends. How do I buy shares of KALA BIO? Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KALA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.